Fig. 4.

Effects of sulforaphane plus 17-AAG on tumor cell activity in vitro and in vivo. (a and b) H1975 cells were treated with the indicated concentrations of 17-AAG in the presence or absence of 4 μM sulforaphane for 24 h. The levels of total (t) and phosphoylated (p) EGFR were assessed by Western blotting (a), and the viability of the treated cells was assessed by the MTT assay (b). The data shown are representative of three experiments with similar results. (c and d) The effect of sulforaphane and 17-AAG treatment on subcutaneous xenografts of H1975 cells in vivo. H1975 cells were injected subcutaneously into the flanks of nude mice (n = 6 per group). Five days later (arrow), the mice were injected with PBS, 25 mg/kg 17-AAG, 10 μmol/kg sulforaphane, or a combination of sulforaphane and 17-AAG. Sulforphane was injected intratumorally five times per week. 17-AAG was administered intraperitoneally three times per week. Tumor volumes were determined twice weekly. The average tumors volumes (c) and body weights (d) were determined for each group. Results shown are the means ± SD of six mice; *p < 0.05; and **p < 0.01, as analyzed with the unpaired t-test